



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/485, 9/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/53825</b> <b>(43) International Publication Date:</b> 3 December 1998 (03.12.98)
<b>(21) International Application Number:</b> PCT/US98/10769 <b>(22) International Filing Date:</b> 26 May 1998 (26.05.98) <b>(30) Priority Data:</b> 60/048,314 27 May 1997 (27.05.97) US <b>(71) Applicant (for all designated States except US):</b> ALGOS PHARMACEUTICAL CORPORATION [US/US]; Collingwood Plaza, 4900 Route 33, Neptune, NJ 07753 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> CARUSO, Frank, S. [US/US]; 2 Bowling Green, Colts Neck, NJ 07722 (US). <b>(74) Agents:</b> DILWORTH, Peter, G. et al.; Dilworth & Barrese, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ANALGESIC DRUG COMPOSITION CONTAINING A CAPSAICINOID AND POTENTIATOR THEREFOR  <b>(57) Abstract</b>  An analgesic drug composition contains at least one analgesic capsaicinoid such as capsaicin and an analgesic potentiator selected from the group consisting of dextromethorphan, dextrorphan and/or pharmaceutically acceptable salt thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5                    ANALGESIC DRUG COMPOSITION CONTAINING A CAPSAICINOID  
                         AND POTENTIATOR THEREFOR

BACKGROUND OF THE INVENTION

                  This invention relates to analgesic drugs and methods of inducing  
analgesia. More particularly, this invention relates to an analgesic drug containing,  
10    as an analgesic component, at least one capsaicinoid and, as a potentiator for the  
capsaicinoid, dextromethorphan, dextrorphan and/or pharmaceutically acceptable  
salt thereof.

                  Capsicum oleoresin, an extract of capsicum (dried red pepper and  
other species of the genus *Capsicum* such as *Capsicum frutescens* and *Capsicum*  
15    *annum*), contains the capsaicinoid capsaicin (*trans*-8-methyl-N-vanillyl-6-  
noneamide). Both capsicum oleoresin and capsicum have for many years been used  
in a variety of over-the-counter topical analgesic medications such as HEET,  
INFRA-RUB, OMEGAOIL and SLOAN's LINIMENT. See also, U.S. Patent No.  
3,880,996 which discloses a topically administered analgesic composition for the  
20    symptomatic relief of localized pain of musculo-skeletal etiology containing, *inter*  
*alia*, capsicum oleoresin.

                  Cutaneous pain and other sensations of inflammatory pain are thought  
to be mediated by substance P, an endogenous neuropeptide. Capsaicin enhances  
the release of substance P from neurons preventing its reaccumulation. As a result  
25    of this effect, capsaicin is believed to render skin insensitive to pain by depleting  
substance P from peripheral sensory neurons. See, Jessell et al., "Capsaicin-  
induced depletion of substance P from primary sensory neurones", *Brain Research*,  
152 (1978) 183-188.

Combinations of capsaicin and an opioid analgesic such as morphine, codeine, hydromorphone, oxycodone, hydrocodone, oxymorphone, propoxyphene, levorphanol, meperidine, fentanyl, methadone, pentazocine, butorphanol and nalbuphine are disclosed in U.S. Patent No. 4,599,342, combinations of capsaicin  
5 and a nonsteroidal antiinflammatory, antipyretic and analgesic drug such as aspirin, salicylic acid, sodium salicylate, methyl salicylate, diflusal, phenylbutazone, indomethacin, zompirac acid, sulindac, fluproquazone, mefenamic acid, ibuprofen, naproxen, ketoprofen, fenoprofen, suprofen, flurbiprofen benoxaprofen, piroprofen, carprofen, acetaminophen and phenacetin are disclosed in U.S. Patent No.  
10 4,681,897 and combinations of capsaicin with the local anesthetic lidocaine or benzocaine are disclosed in U.S. Patent No. 4,997,843.

Delivery vehicles for topically administered drugs such as capsaicin and capsicum include the gels disclosed in U.S. Patent Nos. 5,178,879, 5,306,504 and 5,420,197. A non-occlusive adhesive patch for the topical administration of  
15 capsicum or other topical medication is disclosed in U.S. Patent No. 5,536,263 and in commonly assigned copending U.S. patent application Serial No. 08/675,348, filed July 3, 1996.

Dextromethorphan is a common ingredient of cough, cold and flu medications due to its antitussive (cough-suppressing) activity. Dextromethorphan  
20 is widely and authoritatively regarded as lacking analgesic activity, one of several pharmacological properties that distinguishes it from the opiate analgesics of the morphine type to which it is structurally related. Thus, Goodman and Gilman's "The Pharmaceutical Sciences", 17th ed., Mack Pub. (1985), page 870 states that "unlike codeine, [dextromethorphan] is devoid of analgesic properties...", "Drug  
25 Evaluations Annual 1998", American Medical Association, 1994, page 469 states that dextromethorphan "...does not have addictive, analgesic, or sedative actions..." and Kirk-Othmer, "Encyclopedia of Chemical Technology", 3rd ed., Vol. 9, John Wiley & Sons (1980), page 551, states that "[i]n the case of 3-methoxy-N-

methylnorphinan, the levorotatory isomer was found to possess both analgetic and antitussive activity whereas the dextrorotatory isomer (dextromethorphan (37)) possessed only antitussive activity." Unlike the opioid analgesics, dextromethorphan in therapeutic dosages does not produce respiratory depression.

5 Even the antitussive effects of dextromethorphan differ from those of the opioid analgesics; thus, e.g., the antitussive effects of the opioid analgesic codeine are antagonized by naloxone but those of dextromethorphan are not. And, unlike the opioid analgesics, dextromethorphan poses so little risk of abuse that it is specifically stated to be a non-scheduled drug (21 U.S.C. §811(g)(2)).

10 The few known exceptions to dextromethorphan's lack of analgesic activity involve specific pain conditions, e.g., mouth pain as disclosed in U.S. Patent No. 4,446,140, dysmenorrhea (vaginal cramps) as disclosed in EPA 81,823 and chronic pain as disclosed in U.S. Patent No. 5,352,683. More recently it has been disclosed in PCT publication WP 96/07412 that while dextromethorphan does  
15 not have general analgesic usefulness when administered alone, it significantly enhances, or potentiates, the analgesic activity of a nonsteroidal antiinflammatory drug (NSAID) or acetaminophen with which it is administered for all types of pain.

#### SUMMARY OF THE INVENTION

20 It is an object of the invention to provide an analgesic drug composition containing, as an analgesic component, a capsaicinoid such as capsaicin and, as a potentiator for the capsaicinoid, dextromethorphan, its active metabolite dextrorphan and/or pharmaceutically acceptable salt thereof.

It is a particular object of the invention to provide various dosage  
25 forms of the foregoing analgesic drug composition including those suitable for oral, parenteral, topical, etc., administration.

It is yet a further object of the invention to provide a nonocclusive drug delivery device for topical administration of the analgesic drug composition herein.

In keeping with these and other objects of the invention, there is provided an analgesic drug composition comprising an analgesia-inducing amount of at least one capsaicinoid possessing analgesic activity and an analgesia-potentiating amount of at least one analgesic potentiator selected from the group consisting of dextromethorphan, dextrorphan and pharmaceutically acceptable salts thereof.


The expression "analgesia-inducing amount" as applied to the capsaicinoid component of the foregoing drug composition shall be understood to mean an amount of capsaicinoid which when administered by itself or in combination with the analgesic potentiator provides significant analgesic effect.

#### BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 is a cross-sectional view of a nonocclusive drug delivery system which can be used for the topical administration of the analgesic drug composition of this invention.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

Among the analgesic capsaicinoids that can be used herein are those of the general formula




wherein  $R_1$  is selected from the group consisting of OH and  $OCH_3$ ,  $R_2$  is selected from the group consisting of OH and



R<sub>3</sub> is selected from the group consisting of a C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl and methyl, X is selected from the group consisting of

5




and R is selected from the group consisting of a C<sub>5</sub>-C<sub>11</sub> alkyl, C<sub>5</sub>-C<sub>11</sub> alkenyl, C<sub>11</sub>-C<sub>23</sub> cis alkenyl, C<sub>11</sub>-C<sub>23</sub> alkynyl, C-C<sub>23</sub> alkadienyl and C<sub>11</sub>-C<sub>23</sub> methylene substituted alkane.

10

Preferred capsaicinoids of the foregoing structure include those wherein both R<sub>1</sub> and R<sub>2</sub> are OH and X is

15



and those wherein R<sub>1</sub> is OCH<sub>3</sub>, R<sub>2</sub> is OH or

20



Preferred R groups include C<sub>7</sub>-C<sub>10</sub> alkyls and trans alkenyls, and C<sub>16</sub>-C<sub>21</sub> cis alkenyls and alkadienyls. The preferred moieties within these groups include C<sub>8</sub>H<sub>17</sub>, C<sub>9</sub>H<sub>17</sub> and C<sub>17</sub>H<sub>33</sub>. Preferred capsaicinoids include N-vanillyl-alkadienamides, N-vanillyl-alkanediényls, and N-vanillyl-cis-monounsaturated alkenamides. Among the capsaicinoids that are preferred for use herein are capsaicin (*trans*-8-methyl-N-vanillyl-6-nonenamide) or capsaicin-containing substance

25

such as capsicum oleoresin and capsicum, synthetic capsaicin (N-vanillylnonanamide), the N-[(substituted phenyl)methyl] alkynylamides of U.S. Patent No. 4,532,139, the methylene substituted-N-[(substituted phenyl)methyl]-alkanamides of U.S. Patent No. 4,544,668, the N-[(substituted  
5 phenyl)methyl]diunsaturated amides of U.S. Patent No. 4,544,669, the nonanoyl vanillylamide succinate of U.S. Patent No. 5,094,782, the N-[(substituted phenyl)methyl]-cis-monounsaturated alkenamides of U.S. Patent No. 5,593,848, the N-vanillylureas of EPA 68,590, the N-vanillylsulfonamides of EPA 68,591, the N-vanillylcarbamates of EPA 68,592 and the hydroxyphenylacetamides of EPA  
10 89,710.

Of the foregoing capsaicinoids, capsaicin is the most preferred.

As stated above, the selected capsaicinoid component of the analgesic drug composition of this invention is potentiated by dextromethorphan, dextrorphan or pharmaceutically acceptable salt thereof, e.g., such acid addition salts as  
15 dextromethorphan hydrobromide and dextrorphan hydrobromide. Of the foregoing, dextromethorphan hydrobromide is preferred due to its ready commercial availability and long history of use in numerous over-the-counter medications.

The analgesic drug composition of this invention must contain an analgesia-inducing amount of capsaicinoid(s), considered to be that amount of  
20 capsaicinoid(s) which, if administered alone, will provide significant analgesic effect or, if below that amount, when administered with the analgesic potentiator will provide significant analgesic effect. Thus, the analgesic potentiator component of the drug composition herein permits the capsaicinoid to be present in an amount which would be ineffective or at best only marginally effective to induce analgesia  
25 were it to be administered alone or, if the capsaicinoid is already at a level which by itself would provide significant analgesic effect, the presence of the potentiator will result in a significant increase in the level and/or duration of analgesia.



With capsaicin as illustrative, the drug composition herein when intended for administration to adult humans can contain from about 0.02 to about 1.0, and preferably from about 0.025 to about 0.05, weight percent capsaicinoid(s).

5 The amount of analgesia potentiator present in the analgesic drug composition of this invention must be at least that which is effective to significantly increase the analgesic effectiveness of the capsaicinoid. With dextromethorphan hydrobromide as illustrative, doses of the analgesic potentiator can vary from about 0.2 to about 2, and preferably from about 0.5 to about 1.0, weight percent.

10 In addition to the capsaicinoid(s) and analgesic potentiator, the analgesic drug composition of this invention can contain one or more additional drug components, e.g., an analgesic of the opioid type as disclosed in U.S. Patent No. 4,599,342, an analgesic of the nonopioid type as disclosed in U.S. Patent No. 4,997,843, a counterirritant (other than a capsaicinoid or source thereof) such as camphor or menthol, a local vasodilator such as histamine dihydrochloride and  
15 methyl nicotinate, etc., present in the usual amounts.

The analgesic drug composition can be formulated for oral, parenteral, topical, etc., administration. Depending upon the particular route of administration, a variety of pharmaceutically-acceptable carriers, well known in the art, can be used to prepare the formulations. These include solid or liquid fillers,  
20 diluents, hydrotropes, surface-active agents, and the like. The amount of carrier employed in conjunction with the capsaicinoid and analgesic potentiator will be such as to provide a practical quantity of these drugs per unit dose.

The drug composition of this invention is especially useful for the treatment of such pains as neuralgias, rheumatoid arthritis, bursitis, myositis,  
25 integumental pain, etc., for which it is administered as a topical preparation, preferably in combination with a penetration enhancer. The drug composition can be formulated as a liquid, paste, ointment, cream, lotion, or gel, e.g., any of the gels disclosed in U.S. Patent Nos. 5,178,879, 5,306,504 and 5,420,197.

The following oleophilic topical ointment provides generally acceptable results:

	<u>Component</u>	<u>Amount(g)</u>
5	capsaicin	0.025 - 0.25
	dextromethorphan hydrobromide	0.5 - 1.0
	white wax	5 - 20
	petrolatum	q.s. to 100

10 The analgesic drug composition can be administered via a non-occlusive adhesive patch, e.g., as disclosed in U.S. Patent No. 5,536,263 and preferably as disclosed in commonly assigned copending U.S. patent application Serial No. 08/675,348, filed July 3, 1996.

An embodiment of the nonocclusive drug delivery device of Serial  
 15 No. 08/675,348 is shown generally in Fig. 1 at 10. The drug delivery device includes a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic barrier layer 11 bonded to, and generally coextensive with, upper surface 12 of open cell, flexible, oleophilic thermoplastic resin foam layer 13. Pressure sensitive adhesive 14 occupies a zone, or stratum, 15 on lower surface 16  
 20 of foam layer 13 for securing the drug delivery device to the skin. Drug composition 18, which is formulated within an oleophilic delivery vehicle, occupies drug depot zone 19 and is separated from adhesive zone 15 by barrier zone 20 which prevents or inhibits migration of the drug composition into adhesive 14. A release liner 17 seals and protects lower surface 16 of the foam layer during the  
 25 residency of drug delivery device 10 within its package. The minimum strength of the bond between barrier layer 11 and foam layer 13 must be sufficient to prevent or inhibit separation, i.e., delamination, of the barrier layer from the foam layer under the sort of flexing and/or stretching forces that may be encountered during

the useful life of the applied device. In general, bond strengths of at least about 2 newtons (N), preferably at least about 3 N and more preferably at least about 5 N will generally provide satisfactory results in this regard. However the bond between layers 11 and 13 may be achieved, it is necessary that the bond itself not result in a significant reduction in the moisture vapor transmission rate (MVTR) of the assembled layers. While known and conventional contact adhesives can readily provide barrier layer-to-foam layer bond strengths of 2 N and greater, they may be disadvantageous in reducing the MVTR of the assembled layers to an unacceptable degree. Accordingly, it is preferred to employ a nonadhesive bonding technique, e.g., one employing heat such as flame bonding that is capable of producing the desired bond strengths but without significantly reducing the MVTR of the composite formed from layers 11 and 13. In general, the MVTR of the barrier layer-foam layer subassembly will be at least about 500, preferably at least about 1000 and more preferably at least about 1200, g/m<sup>2</sup>/24 h at 100% r.h. and 32°C as measured by ASTM F1249-90.

Another requirement of drug delivery device 10 is that whatever the bond strength between barrier layer 11 and foam layer 13, the contact adhesive must impart a peel strength to the drug delivery device, i.e., the amount of force required to peel the spent drug delivery device from the skin, which is less, preferably at least about 20 percent less and more preferably at least about 40 percent less, than such bond strength in order to prevent or minimize the separation of the barrier layer from the foam layer when the spent drug delivery device is peeled from the skin. Barrier layer 11 can be any thermoplastic film possessing an MVTR of one of the aforestated values. Preferably, the barrier layer can be a polyurethane film possessing an average thickness of from about 0.5 to about 3.5 mils and preferably from about 1.0 to about 1.5 mils and a tensile strength of at least about 2500 psi and preferably at least about 3500 psi.

Foam layer 13 in its as-manufactured state is an open cell, flexible, oleophilic foam that provides a stable matrix for the analgesic drug composition herein particularly when the drug is formulated in an oleophilic delivery vehicle. By "stable matrix" is meant that property of the foam which, owing to its oleophilic character, enables the foam to function not only as a depot, or reservoir, for the oleophilic drug composition, but confines the composition to zone 19 which is separated by barrier zone 20 from zone 15 occupied by pressure sensitive adhesive 14. Thus, the oleophilic characteristics of the foam layer prevent or inhibit migration of drug composition 18 into adhesive zone 15 where it could destroy or impair the effectiveness of adhesive 14 in securing the drug delivery device to the skin. Another advantageous characteristic of the drug delivery device herein is its ability to maintain continuous contact between the drug composition and the skin thus assuring that the drug will be constantly available at the site of its administration.

In general, the useful foams possess a density of from about 0.8 to about 8.0 and preferably from about 1.2 to about 4.8 lb/ft, a number of pores per inch of from about 30 to about 120 and preferably from about 60 to about 90, and can be fully or partially reticulated or nonreticulated. The average thickness of the foam layer can vary from about 30 to about 100 mils and for many applications is preferably from about 40 to about 70 mils. Suitable foams that can be employed herein include the untreated oleophilic (i.e, hydrophobic) open cell polyurethane foams disclosed in U.S. Patent No. 5,352,711.

Pressure sensitive adhesive 14 can be selected from any of the known and conventional medical grade adhesives, e.g., those based on polyacrylic, polyvinylether, or polyurethane resins. It is an essential requirement that the amount of adhesive 14 applied to zone 15 of foam layer 13 be sufficient to achieve an acceptable level of adhesion of drug delivery device 10 to the skin but, as previously stated, with a resulting peel strength that is sufficiently below the bond


strength between the barrier and foam layers. The amount of adhesive that will satisfy these criteria can be readily determined by simple and routine testing.

- Ordinarily, a medical grade polyacrylic adhesive such as Durotak® (National Starch & Chemical Company, Bridgewater, NJ) or Gelva® (Monsanto Inc., St. Louis, MO) applied to a thickness of from about 1 to about 3.5 mils and preferably from about 2.0 to about 2.5 mils (depending, of course, on the thickness of the foam layer), or applied at a rate of from about 25 to about 100 g/cm<sup>2</sup> and preferably from about 50 to about 65 g/cm<sup>2</sup>, will meet these requirements reasonably well.
- 5

WHAT IS CLAIMED IS:

1. An analgesic drug composition comprising an analgesia-inducing amount of at least one capsaicinoid possessing analgesic activity and an analgesia-potentiating amount of at least one analgesic potentiator selected from the group consisting of dextromethorphan, dextrorphan and pharmaceutically acceptable salts thereof.


2. The analgesic drug composition of Claim 1 wherein the capsaicinoid possesses the general formula



wherein  $R_1$  is selected from the group consisting of OH and  $OCH_3$ ,  $R_2$  is selected from the group consisting of OH and



$R_3$  is selected from the group consisting of a  $C_1$ - $C_4$  alkyl, phenyl and methyl, X is selected from the group consisting of



and R is selected from the group consisting of a  $C_5$ - $C_{11}$  alkyl,  $C_5$ - $C_{11}$  alkenyl,  $C_{11}$ - $C_{23}$  cis alkenyl,  $C_{11}$ - $C_{23}$  alkynyl,  $C$ - $C_{23}$  alkadienyl and  $C_{11}$ - $C_{23}$  methylene substituted alkane.

3. The analgesic drug composition of Claim 1 wherein the capsaicinoid is capsaicin.
4. The analgesic drug composition of Claim 1 in a topical drug delivery dosage form.
- 5 5. The analgesic drug composition of Claim 4 containing a penetration enhancer.
6. The analgesic drug composition of Claim 4 in an oleophilic carrier.
7. The analgesic drug composition of Claim 4 wherein the  
10 capsaicinoid is capsaicin.
8. The analgesic drug composition of Claim 4 wherein the analgesic potentiator is dextromethorphan or pharmaceutically acceptable salt thereof.
9. A nonocclusive drug delivery device for the delivery of a  
15 capsaicinoid-containing analgesic drug composition which comprises:
  - a) an open cell, flexible, oleophilic thermoplastic resin foam layer possessing upper and lower surfaces and predetermined adhesive and drug depot zones, the drug depot zone containing an analgesia-inducing amount of a capsaicinoid-containing analgesic drug composition which comprises at least one  
20 capsaicinoid possessing analgesic activity and an analgesia-potentiating amount of at least one analgesia potentiator selected from the group consisting of dextromethorphan, dextrorphan and pharmaceutically acceptable salts thereof;

b) a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic barrier layer bonded to the upper surface of the foam layer, the composite of the barrier and foam layers possessing a moisture vapor transmission rate of at least about  $500 \text{ g/m}^2/24 \text{ h}$  at 100% r.h and  $32^\circ\text{C}$ , the bond strength between the barrier layer and the foam layer being such as to resist separation of the barrier layer from the foam layer when the drug delivery device is subjected to the flexing and/or stretching forces normally encountered during its useful applied life; and,

c) a pressure sensitive adhesive within the adhesive zone of the foam layer, the adhesive layer imparting a peel strength to the drug delivery device which is sufficiently below that of the bond strength between the foam layer and the barrier layer such that upon peeling the device from the skin, substantially all of the foam layer remains bonded to the barrier layer.

10. The drug delivery device of Claim 9 wherein the capsaicinoid is capsaicin.

11. The drug delivery device of Claim 10 in an oleophilic carrier.

12. The drug delivery device of Claim 10 wherein the analgesic potentiator is dextromethorphan or pharmaceutically acceptable salt thereof.

13. A method for inducing analgesia in a mammal which comprises topically administering to a mammal in need of analgesia an analgesic drug composition comprising an analgesia-inducing amount of at least one capsaicinoid possessing analgesic activity and an analgesia-potentiating amount of at least one analgesic potentiator selected from the group consisting of dextromethorphan, dextrorphan and pharmaceutically acceptable salts thereof.

14. The method of Claim 13 wherein the capsaicinoid is capsaicin.


15. The method of Claim 14 wherein the analgesic potentiator is dextromethorphan or pharmaceutically acceptable salt thereof.



16. The method of Claim 13 wherein the analgesic drug composition is delivered by the nonocclusive drug delivery device which comprises:

- 5 a) an open cell, flexible, oleophilic thermoplastic resin foam layer possessing upper and lower surfaces and predetermined adhesive and drug depot zones, the drug depot zone containing an analgesia-inducing amount of the analgesic drug composition;
- 10 b) a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic barrier layer bonded to the upper surface of the foam layer, the composite of the barrier and foam layers possessing a moisture vapor transmission rate of at least about  $500 \text{ g/m}^2/24 \text{ h}$  at 100% r.h and  $32^\circ\text{C}$ , the bond strength between the barrier layer and the foam layer being such as to resist separation of the barrier layer from the foam layer when the drug delivery device is subjected to the flexing and/or stretching forces normally encountered during its useful applied life; and,
- 15 c) a pressure sensitive adhesive within the adhesive zone of the foam layer, the adhesive layer imparting a peel strength to the drug delivery device which is sufficiently below that of the bond strength between the foam layer and the barrier layer such that upon peeling the device from the skin, substantially all of the foam layer remains bonded to the barrier layer.

1/1

**Fig. 1**

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/485 A61K9/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 00117 A (ALGOS PHARM CORP) 8 January 1998	9, 11
A	see claims; figures ---	16
X	WO 97 04780 A (UNIV VIRGINIA COMMONWEALTH) 13 February 1997 see page 1, line 7-10; claims 1, 8, 15, 17 see page 1, line 20-24 see page 3, line 28 - page 4, line 18 see page 6, line 21-27 see page 7, line 27 - page 8, line 9 see page 8, line 25-32 --- -/--	1, 8, 13, 15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 September 1998

Date of mailing of the international search report

02/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 02273 A (PROCTER & GAMBLE) 23 January 1997 see page 5, line 1-31; claims 5,6 see page 7, line 28 - page 8, line 3 see page 8, line 20-36 see page 9, line 24-32; examples 3,4 ---	1-4,6-8
A	US 4 599 342 A (LAHANN THOMAS R) 8 July 1986 see column 2-4; claims 1-11,25 ---	1-4,13, 14
A	WO 97 10815 A (FROME BRUCE M) 27 March 1997 see page 1, paragraph 1 see page 7, paragraph 2-5 see page 11; claims 1,2,11 see page 30, paragraph 3 ---	1,4,6,8, 13,15
A	US 4 557 934 A (COOPER EUGENE R) 10 December 1985 see column 18, line 33-56; claim 11 ---	1-7, 13-16
A	US 5 505 958 A (ALGOS PHARMACEUTICALS) 9 April 1996 ---	9,11,16
A	US 4 455 146 A (NODA KANJI ET AL) 19 June 1984  see column 4; example 4 see column 3, line 36-42 ---	1-4,6,7, 9-11,13, 14,16
A	US 5 273 757 A (JAEGER HALVOR ET AL) 28 December 1993 see column 4, line 64 - column 5, line 6 see column 6, line 66-67; claims; figures ---	9-11,16
A	US 5 589 180 A (HIND HARRY) 31 December 1996 see column 4, line 54-62 see column 1, line 35-39 see column 7; claims ---	9-11,16
A	US 5 336 213 A (D ANGELO JOSEPH P ET AL) 9 August 1994 see column 1, line 51-56; claims; figures ---	9,12,16
A	US 5 332 576 A (MANTELLE JUAN A) 26 July 1994 see column 18, line 37 - column 20, line 21 -----	9,12,16

# INTERNATIONAL SEARCH REPORT

International application no.

PCT/US 98/ 10769

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 1-16  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9800117 A	08-01-1998	US 5716621 A AU 3718797 A	10-02-1998 21-01-1998
WO 9704780 A	13-02-1997	AU 6686596 A EP 0845989 A	26-02-1997 10-06-1998
WO 9702273 A	23-01-1997	AU 6276996 A EP 0837862 A	05-02-1997 29-04-1998
US 4599342 A	08-07-1986	AU 561804 B AU 3757385 A CA 1241600 A DK 19285 A EP 0149544 A GB 2152815 A,B JP 60214733 A	14-05-1987 25-07-1985 06-09-1988 17-07-1985 24-07-1985 14-08-1985 28-10-1985
WO 9710815 A	27-03-1997	NONE	
US 4557934 A	10-12-1985	AU 560908 B AU 2955784 A CA 1223819 A EP 0129284 A JP 60036422 A	16-04-1987 03-01-1985 07-07-1987 27-12-1984 25-02-1985
US 5505958 A	09-04-1996	NONE	
US 4455146 A	19-06-1984	JP 55133310 A JP 1497913 C JP 55141408 A JP 63046725 B CA 1132455 A DE 3007368 A FR 2452935 A GB 2045618 A,B NL 8001223 A,C	17-10-1980 29-05-1989 05-11-1980 19-09-1988 28-09-1982 23-10-1980 31-10-1980 05-11-1980 07-10-1980
US 5273757 A	28-12-1993	DE 3743945 A AU 2139688 A AU 636835 B	09-03-1989 31-03-1989 13-05-1993

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5273757      A		AU      2250688 A	31-03-1989
		AU      636836 B	13-05-1993
		AU      2253188 A	31-03-1989
		CA      1333688 A	27-12-1994
		CA      1329363 A	10-05-1994
		CA      1333052 A	15-11-1994
		CS      8805872 A	16-12-1992
		CZ      281743 B	15-01-1997
		CZ      8805874 A	19-01-1994
		DD      282182 A	05-09-1990
		DD      273003 A	01-11-1989
		DD      280047 A	27-06-1990
		DE      3743946 A	09-03-1989
		DE      3743947 A	09-03-1989
		DE      3876898 A	04-02-1993
		DE      3886477 D	03-02-1994
		DE      3886478 D	03-02-1994
		WO      8901787 A	09-03-1989
		WO      8901788 A	09-03-1989
		WO      8901789 A	09-03-1989
		DK      210289 A	28-04-1989
		DK      210389 A	28-04-1989
		DK      210489 A	28-04-1989
		EP      0305756 A	08-03-1989
		EP      0305757 A	08-03-1989
		EP      0305758 A	08-03-1989
		ES      2047511 T	01-03-1994
		ES      2047512 T	01-03-1994
		FI      892053 A,B,	28-04-1989
		FI      892054 A,B,	28-04-1989
		FI      892055 A,B,	28-04-1989
		GR      3006666 T	30-06-1993
		HR      920832 A	31-10-1994
		HR      920852 A	28-02-1995
		HR      920857 A	31-10-1994
		IE      62943 B	08-03-1995
		IE      64538 B	23-08-1995
		IE      66100 B	13-12-1995
		IL      87538 A	27-02-1994
		IL      87540 A	27-02-1994

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5273757 A		JP 2500594 T	01-03-1990
		JP 2781579 B	30-07-1998
		JP 2500569 T	01-03-1990
		JP 2718531 B	25-02-1998
		JP 2500595 T	01-03-1990
		KR 9706446 B	28-04-1997
		KR 9706447 B	28-04-1997
US 5589180 A	31-12-1996	US 5411738 A	02-05-1995
		US 5601838 A	11-02-1997
		US 5709869 A	20-01-1998
		AT 161735 T	15-01-1998
		CA 1338779 A	10-12-1996
		DE 69031879 D	12-02-1998
		DE 69031879 T	20-05-1998
		EP 0388306 A	19-09-1990
		ES 2110963 T	01-03-1998
		JP 2300138 A	12-12-1990
		JP 2515902 B	10-07-1996
US 5336213 A	09-08-1994	US 5756117 A	26-05-1998
		US 5405614 A	11-04-1995
		US 5505957 A	09-04-1996
		AU 4045993 A	18-11-1993
		CA 2110903 A	28-10-1993
		EP 0593746 A	27-04-1994
		JP 6508379 T	22-09-1994
		WO 9320787 A	28-10-1993
		US 5614212 A	25-03-1997
US 5332576 A	26-07-1994	US 5234957 A	10-08-1993
		AT 144704 T	15-11-1996
		AU 658870 B	04-05-1995
		AU 1461092 A	06-10-1992
		AU 694243 B	16-07-1998
		AU 2833195 A	28-09-1995
		CA 2104474 A	28-08-1992
		DE 69214938 D	05-12-1996
		DE 69214938 T	15-05-1997
		DK 573576 T	01-04-1997



Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5332576 A		EP 0573576 A	15-12-1993
		EP 0728477 A	28-08-1996
		ES 2094906 T	01-02-1997
		FI 933761 A	26-08-1993
		GR 3022708 T	31-05-1997
		JP 6508820 T	06-10-1994
		NO 933296 A	01-11-1993
		SG 49158 A	18-05-1998
		WO 9215289 A	17-09-1992
		US 5446070 A	29-08-1995
		US 5719197 A	17-02-1998

---